Evidence map›Paper›PMID 22171844›Full record

ArticleBMC infectious diseases2011

Latent tuberculosis infection, tuberculin skin test and vitamin D status in contacts of tuberculosis patients: a cross-sectional and case-control study.

Alberto Arnedo-Pena, José Vicente Juan-Cerdán, Angeles Romeu-Garcia, Daniel Garcia-Ferrer, Rita Holguín-Gómez, Jesús Iborra-Millet, Concepción Herrero-Carot, María Jesús Sanchis Piñana, Juan Bellido-Blasco, José Antonio Ferrero-Vega and 4 more

Abstract read
In one paragraph

Article in BMC infectious diseases, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed, 5 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 5 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Trial
  7. Infectious and clinical tuberculosis trajectories: Bayesian modeling with case finding implications.Proceedings of the National Academy of Sciences of the United States of America · 2022
    Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Effect of DOTS Treatment on Vitamin D Levels in Pulmonary Tuberculosis.Journal of clinical and diagnostic research : JCDR · 2017
    Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Alberto Arnedo-PenaEpidemiology Division, Public Health Center Castellón, Spain. arnedo_alb@gva.es
José Vicente Juan-Cerdán
Angeles Romeu-Garcia
Daniel Garcia-Ferrer
Rita Holguín-Gómez
Jesús Iborra-Millet
Concepción Herrero-Carot
María Jesús Sanchis Piñana
Juan Bellido-Blasco
José Antonio Ferrero-Vega
Lourdes Safont Adsuara
Esther Silvestre Silvestre
Noemi Meseguer Ferrer
Vicenta Rodrigo Bartual

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDeficient serum vitamin D levels have been associated with incidence of tuberculosis (TB), and latent tuberculosis infection (LTBI). However, to our knowledge, no studies on vitamin D status and tuberculin skin test (TST) conversion have been published to date. The aim of this study was to estimate the associations of serum 25-hydroxyvitamin D3 (25[OH]D) status with LTBI prevalence and TST conversion in contacts of active TB in Castellon (Spain).

methodsThe study was designed in two phases: cross-sectional and case-control. From November 2009 to October 2010, contacts of 42 TB patients (36 pulmonary, and 6 extra-pulmonary) were studied in order to screen for TB. LTBI and TST conversion cases were defined following TST, clinical, analytic and radiographic examinations. Serum 25(OH)D levels were measured by electrochemiluminescence immunoassay (ECLIA) on a COBAS® 410 ROCHE® analyzer. Logistic regression models were used in the statistical analysis.

resultsThe study comprised 202 people with a participation rate of 60.1%. Only 20.3% of the participants had a sufficient serum 25(OH)D (≥ 30 ng/ml) level. In the cross-sectional phase, 50 participants had LTBI and no association between LTBI status and serum 25(OH)D was found. After 2 months, 11 out of 93 negative LTBI participants, without primary prophylaxis, presented TST conversion with initial serum 25(OH)D levels: a:19.4% (7/36): < 20 ng/ml, b:12.5% (4/32):20-29 ng/ml, and c:0%(0/25) ≥ 30 ng/ml. A sufficient serum 25(OH)D level was a protector against TST conversion a: Odds Ratio (OR) = 1.00; b: OR = 0.49 (95% confidence interval (CI) 0.07-2.66); and c: OR = 0.10 (95% CI 0.00-0.76), trends p = 0.019, adjusted for high exposure and sputum acid-fast bacilli positive index cases. The mean of serum level 25(OH)D in TST conversion cases was lower than controls,17.5 ± 5.6 ng/ml versus 25.9 ± 13.7 ng/ml (p = 0.041).

conclusionsThe results suggest that sufficient serum 25(OH)D levels protect against TST conversion.

Indexed as

Tuberculin TestAdultCalcifediolCase-Control StudiesContact TracingCross-Sectional StudiesFemaleHumansLatent TuberculosisLogistic ModelsMaleMiddle AgedPrevalenceRisk FactorsSpainTuberculosis, PulmonaryCalcifediol

Identifiers

PMID22171844
PMCPMC3292546

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.